Figure 6.

Drug screen with FDA-approved anti-cancer compounds on IDHmt glioma cultures. (A) Heatmap of response of IDHmt glioma cultures (N = 7) to an FDA-approved anti-cancer drug set. Sensitive cell cultures (blue) were defined as having an IC₅₀ < C_max plasma, while resistant cultures (yellow) had IC₅₀ > C_max. All drugs were tested with a 10-fold dilution series of six concentrations, in technical duplicates. (B) Dose-response curves of the anti-cancer compounds gemcitabine, paclitaxel, teniposide, daunorubicin, romidepsin, dactinomycin, regorafenib, omacetaxine and marizomib, on all IDHmt cell cultures (N = 12). The X-axes represent increasing concentrations of the respective compounds. The Y-axes indicate the percentage cell viability compared to DMSO-treated controls. All drugs were tested in 3-fold dilution series with 8 concentrations. Error bars represent standard deviation of technical quadruplicates. At least two biological replicates of the screens were performed for each cell culture. (C) IC₅₀ values were calculated based on the dose-response curves shown in Figure 6B. All values represent the drug concentration in µM. Red numbers indicate IC₅₀ > C_max and are labelled as resistant.